Idogen AB

ST:IDOGEN Sweden Biotechnology & Medical Research
Market Cap
$1.12 Million
Skr12.58 Million SEK
Market Cap Rank
#36178 Global
#590 in Sweden
Share Price
Skr0.12
Change (1 day)
+0.00%
52-Week Range
Skr0.12 - Skr0.12
All Time High
Skr7.44
About

Idogen AB (publ), a biotechnology company, develops tolerogenic cell therapies to prevent the patient's immune system from attacking biological agents, transplanted organs, and the body's own cells or tissues in Sweden. The company's advanced product candidate is IDO 8 that is designed for patients with severe haemophilia A, who have developed neutralizing antibodies against critical treatment wi… Read more

Idogen AB (IDOGEN) - Total Liabilities

Latest total liabilities as of March 2023: Skr3.09 Million SEK

Based on the latest financial reports, Idogen AB (IDOGEN) has total liabilities worth Skr3.09 Million SEK as of March 2023.

Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Idogen AB - Total Liabilities Trend (2014–2022)

This chart illustrates how Idogen AB's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.

Idogen AB Competitors by Total Liabilities

The table below lists competitors of Idogen AB ranked by their total liabilities.

Company Country Total Liabilities
Advanced Health Intelligence Ltd.
OTCGREY:MYZQF
USA $10.26 Million
Seya Industries Limited
NSE:SEYAIND
India ₹7.87 Billion
BAVARIA INDUSTR
MU:B8A
Germany €51.29 Million
Argent
JSE:ART
South Africa ZAC899.39 Million
International Prospect Ventures Ltd
PINK:URANF
USA $239.03K
CKALF
PINK:CKALF
USA $53.44 Million
PRYSMIAN - Dusseldorf Stock Exchang
DU:AEU
Germany €9.42 Billion

Liability Composition Analysis (2014–2022)

This chart breaks down Idogen AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 1.66 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 1.52 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.60 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Idogen AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Idogen AB (2014–2022)

The table below shows the annual total liabilities of Idogen AB from 2014 to 2022.

Year Total Liabilities Change
2022-12-31 Skr5.38 Million -55.44%
2021-12-31 Skr12.08 Million +18.20%
2020-12-31 Skr10.22 Million -20.51%
2019-12-31 Skr12.86 Million -37.73%
2018-12-31 Skr20.65 Million +380.39%
2017-12-31 Skr4.30 Million +107.49%
2016-12-31 Skr2.07 Million +86.48%
2015-12-31 Skr1.11 Million +115.13%
2014-12-31 Skr516.43K --